English

24 MAY
SÃO PAULO – SP - BRAZIL
(NOVOTEL MORUMBI)

PARTICIPANTS PROFILE

Product categories

Branded generics: 37.5%

Biological products: 35.9%

Biosimilars: 26.6%

Hospital products: 31.3%

Innovative medicines: 51.6%

more info




Partnering Strategy/Interests

In-licensing: 45.3%

Out-licensing: 32.8%

Co-marketing: 28.1%

Co-promotion: 29.7%

Co-development: 39.1%

more info




Therapeutic areas

Cardiovascular: 45.3%

CNS: 54.7%

Infectious diseases: 34.4%

Pain: 46.9%

Respiratory: 31.3%

more info



PARTICIPANTS 2016

Allergy/immunology: 16.4%

Cardiovascular: 45.3%

CNS: 54.7%

Dentistry: 5.5%

Dermatology: 12.5%

Drug delivers technol.: 22.7%

Gastroenterology: 18.0%

Gerontology: 9.4%

Gynecology: 20.3%

Infectious diseases: 34.4%

Hematology: 14.6%

Ophthalmology: 10.9%

Oncology: 21.9%

Orthopedics: 12.5%

Pain: 46.9%

Pediatrics: 9.4%

Psychiatrics: 17.2%

Respiratory: 31.3%

Rheumatology: 15.6%

Urology: 11.7%

Vaccines: 7.8%

partner